| Overall (n = 151) | DEXA+ (n = 84) | DEXA− (n = 67) |
---|---|---|---|
Male, n (%) | 120 (79) | 65 (77) | 55 (82) |
Age, years ± SD | 64 ± 12 | 66 ± 11 | 62 ± 13 |
SAPS 2, mean ± SD | 42 ± 14 | 42 ± 13 | 42 ± 15 |
SOFA, mean ± SD | 6 ± 4 | 5 ± 4 | 6 ± 3 |
Comorbidities, n (%) | Â | Â | Â |
 Hypertension | 73 (48) | 43 (51) | 30 (45) |
 Diabetes mellitus | 55 (36) | 34 (40) | 21 (31) |
 Obesity | 44 (29) | 24 (29) | 20 (30) |
 Smoker | 37 (25) | 18 (21) | 19 (28) |
 Chronic heart failure | 27 (18) | 12 (14) | 15 (22) |
 Chronic respiratory failure | 20 (13) | 11 (13) | 9 (13) |
 History of neoplasm | 18 (12) | 12(14) | 6 (9) |
 Immunosuppression | 11 (7) | 6 (7) | 5 (7) |
 Chronic renal failure | 9 (6) | 6 (7) | 3 (4) |
Antiviral agents, n (%) | 22 (15) | 0 | 22 (33) |
 Lopinavir–ritonavir | 21 (14) | 0 | 21 (31) |
 Remdesivir | 1 (1) | 0 | 1 (2) |
Hydroxychloroquine, n (%) | 37 (25) | 2 (2) | 35 (52) |
Antimicrobial treatment at ICU admission, n (%) | 110 (73) | 52 (62) | 58 (87) |
Documented co-infection, n (%) | 16 (11) | 6 (7) | 9 (13) |
Time from hospital admission to ICU admission, days, median (IQR) | 0 (0–2) | 0 (0–2) | 0 (0–2) |
Invasive MV at ICU admission, n (%) | 70 (46) | 30 (36) | 40 (60) |
Time to intubation, days, median (IQR) | 1 (0–2) | 1 (0–4) | 0 (0–1) |
Time from dexamethasone to intubation, days, median (IQR) | – | 1 (0–4) | – |
ECMO, n (%) | 29 (19) | 15 (18) | 14 (21) |
Hydrocortisone for septic shock, n (%) | 27 (18) | 11 (13) | 16 (24) |